Mai, Elias K. http://orcid.org/0000-0002-6226-1252
Huhn, Stefanie
Miah, Kaya http://orcid.org/0000-0002-0265-3529
Poos, Alexandra M.
Scheid, Christof
Weisel, Katja C. http://orcid.org/0000-0001-9422-6614
Bertsch, Uta
Munder, Markus
Berlanga, Oscar
Hose, Dirk
Seckinger, Anja
Jauch, Anna
Blau, Igor W.
Hänel, Mathias
Salwender, Hans J. http://orcid.org/0000-0001-7803-0814
Benner, Axel
Raab, Marc S. http://orcid.org/0000-0003-4181-6922
Goldschmidt, Hartmut http://orcid.org/0000-0003-0961-0035
Weinhold, Niels
Funding for this research was provided by:
International Myeloma Society Career Development Award 2021
Dietmar Hopp Stiftung (n/a)
see above
Article History
Received: 14 September 2022
Revised: 8 December 2022
Accepted: 12 December 2022
First Online: 4 January 2023
Conflict of interest
: E.K.M.: Consulting or Advisory Role, Honoraria, Research Funding, and Travel Accommodations and Expenses—Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi, Stemline and Takeda. Oscar Berlanga is an employee of The Binding Site Group Ltd., UK. M.H.: Consulting or Advisory Role, Honoraria: Amgen, Bayer Vital, Celgene, Gilead, Glaxo Smith Kline, Jazz Pharmaceuticals, Novartis, Roche, Takeda. H.J.S.: Honoraria: AbbVie, Amgen, AstraZeneca, BMS, Celgene, Chugai, GSK, Janssen, Oncopeptides, Pfizer, Sanofi, Sebia, TAD, Takeda; Travel, accommodations, expenses: Amgen, BMS, Celgene, Janssen, and Sanofi. The remaining authors declare no conflict of interest.